



MiDOS

Neutropenia Prediction Assay

Predicts neutropenia 3 days before onset

Unique patented blood test kits

Minimally invasive peripheral blood test

NEED FOR MiDOS

- Neutropenia is a chronic condition where the immune system is severely compromised
- Cancer treatments like chemotherapy and radiation therapy lead to neutropenia in ~78% of cases, 70% rehospitalizations, 8% fatality

CHROMOLOGIC ADVANTAGE

- Prophylactic treatments are expensive and have many side effects
- NO predictive test / Assay

MARKET OPPORTUNITY

- \$10 Billion market opportunity (global)
- Established reimbursement model in U.S



216,530

Lives saved

2.7 Billion

Patients impacted

\$1.5 Billion

Annual savings to U.S. healthcare